Moderna Embarks On Phase 2 Study Of Covid-19 Candidate; Shares Pop 11%

Moderna Inc. (MRNA) announced that it has started dosing the first patients in a Phase 2 study with its experimental mRNA-1273 vaccine candidate against the novel coronavirus. Shares shot up 11% to $…
Read More